XML 259 R215.htm IDEA: XBRL DOCUMENT v3.22.4
Segment information - Schedule of Segment Results (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of operating segments [line items]      
Net sales € 42,997 € 37,761 € 36,041 [1]
Other revenues 2,392 1,414 1,328 [1]
Cost of sales (13,695) (12,255) (12,159) [1]
Research and development expenses (6,706) (5,692) (5,530) [1]
Selling and general expenses (10,492) (9,555) (9,391) [1]
Share of profit/(loss) from investments accounted for using the equity method 68 39 359
Net income attributable to non-controlling interests 113 56 [2] 36 [2],[3]
Pharmaceuticals      
Disclosure of operating segments [line items]      
Net sales 30,688 26,970 25,674
Other revenues 657 264 128
Cost of sales (7,511) (6,965) (6,982)
Research and development expenses (5,067) (4,330) (4,171)
Selling and general expenses (5,923) (5,326) (4,927)
Other operating income and expenses (1,800) (1,172) (487)
Share of profit/(loss) from investments accounted for using the equity method 28 17 5
Net income attributable to non-controlling interests (29) (49) (33)
Business operating income 11,043 9,409 9,207
Vaccines      
Disclosure of operating segments [line items]      
Net sales 7,229 6,323 5,973
Other revenues 1,666 1,095 1,141
Cost of sales (4,101) (3,430) (3,312)
Research and development expenses (936) (712) (682)
Selling and general expenses (870) (805) (789)
Other operating income and expenses 132 128 3
Share of profit/(loss) from investments accounted for using the equity method 48 11 2
Net income attributable to non-controlling interests 0 (1) 0
Business operating income 3,168 2,609 2,336
Consumer Healthcare      
Disclosure of operating segments [line items]      
Net sales 5,080 4,468 4,394
Other revenues 62 55 59
Cost of sales (1,827) (1,606) (1,528)
Research and development expenses (187) (153) (153)
Selling and general expenses (1,478) (1,388) (1,419)
Other operating income and expenses 152 111 53
Share of profit/(loss) from investments accounted for using the equity method 12 11 9
Net income attributable to non-controlling interests (4) (5) (5)
Business operating income 1,810 1,493 1,410
Other      
Disclosure of operating segments [line items]      
Net sales 0 0 0
Other revenues 7 0 0
Cost of sales (253) (250) (284)
Research and development expenses (516) (497) (524)
Selling and general expenses (2,221) (2,036) (2,256)
Other operating income and expenses 2 (13) (130)
Share of profit/(loss) from investments accounted for using the equity method 0 0 0
Net income attributable to non-controlling interests 0 (1) 0
Business operating income (2,981) (2,797) (3,194)
Total Sanofi      
Disclosure of operating segments [line items]      
Net sales 42,997 37,761 36,041
Other revenues 2,392 1,414 1,328
Cost of sales (13,692) (12,251) (12,106)
Research and development expenses (6,706) (5,692) (5,530)
Selling and general expenses (10,492) (9,555) (9,391)
Other operating income and expenses (1,514) (946) (561)
Share of profit/(loss) from investments accounted for using the equity method 88 39 16
Net income attributable to non-controlling interests (33) (56) (38)
Business operating income € 13,040 € 10,714 € 9,759
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[2] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[3] (j)    Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.